IR情報

2022/08/02~2022/12/27

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2022
12/27250259250258+1.98%163,00078億7608万-2.27%
12/26243258243253+2.43%323,20077億2345万-4.89%
12/23237247234247+3.35%222,20075億4028万-8.18%
12/22243245237239-1.24%185,30072億9606万-12.13%
12/21244249242242-1.22%131,00072億9119万-12%
12/20253257240245-3.92%507,40073億8158万-12.19%
12/19266267255255-3.04%299,70076億8287万-9.57%
12/1615:00 緑内障治療剤「H-1337」の米国後期第II相臨床試験の治験届提出のお知らせ
12/16261267260263-0.75%133,10079億2390万-7.39%
12/15255267253265+3.92%321,50079億8416万-7.02%
12/14255259254255-1.16%172,50076億8287万-11.15%
12/13258264252258+1.98%395,70077億7325万-11.03%
12/1215:00 ラクオリア創薬株式会社との共同研究契約締結のお知らせ
12/122522532492530%158,80076億2261万-13.36%
12/09251257248253+1.2%258,10076億2261万-14.24%
12/08260260248250-3.47%507,70075億3222万-16.39%
12/07283288254259-0.38%2,316,40078億338万-14.24%
12/0615:00 緑内障・高眼圧症治療剤「グラアルファ配合点眼液」国内販売開始のお知らせ
12/06267267260260-1.89%184,40078億3351万-14.47%
12/05268270263265-1.12%153,60079億8416万-13.96%
12/02273274263268-1.47%259,90080億7454万-13.55%
12/01273279270272-0.73%242,60081億9506万-12.82%
11/30278278269274-2.14%387,10082億5532万-12.74%
11/29279285277280-1.41%203,30084億3609万-11.39%
11/28293295280284-3.4%442,40085億5661万-10.69%
11/25301303294294-2%355,10088億5789万-7.84%
11/24308308297300-1.64%375,00090億3867万-6.25%
11/223043113033050%303,70091億8931万-4.98%
11/21339342304305-7.01%1,072,00090億5098万-4.98%
11/1815:30 当社子会社(日本革新創薬株式会社)の角膜内皮治療薬の実施権譲渡のお知らせ
11/1815:30 業績予想の修正に関するお知らせ
11/18325335321328-0.91%394,60097億3351万+2.18%
11/17338357323331+3.76%2,276,10098億2254万+3.76%
11/1615:00 緑内障・高眼圧症治療剤「グラアルファ配合点眼液」薬価収載のお知らせ
11/16327328319319-1.54%185,80094億6644万+0.31%
11/15320328317324+0.62%200,10096億1481万+1.89%
11/14308327305322+4.55%359,70095億5546万+1.26%
11/11297313296308+1.65%269,30091億4001万-3.75%
11/1015:30 2022年12月期第3四半期決算短信〔日本基準〕(連結)
11/10307314303303-1.62%191,60089億9163万-5.02%
11/09317317301308-3.14%307,30091億4001万-2.84%
11/08322327318318-1.24%205,40094億3676万+0.63%
11/07331331318322-3.3%501,80095億5546万+3.21%
11/04328338324333-0.3%230,80098億8189万+7.77%
11/02323341315334+3.41%464,80099億1157万+9.51%
11/01330333317323-2.12%415,70095億8514万+7.31%
10/31344353330330-2.94%607,20097億9287万+10.74%
10/28335341325340+1.8%633,400100億8962万+15.65%
10/27316336315334+5.03%580,30099億1157万+15.17%
10/263193283173180%311,20094億3676万+11.19%
10/25313322309318+1.27%190,10094億3676万+12.37%
10/24325326309314-3.38%313,30093億1806万+12.54%
10/21315326315325+3.83%289,20095億6566万+17.75%
10/20325329313313-5.15%384,40092億1246万+15.07%
10/19309335309330+6.11%744,10097億1282万+22.68%
10/18306312301311+0.65%236,30091億5360万+17.36%
10/17301313297309+2.66%290,30090億9473万+17.94%
10/14299308292301+1.69%320,70088億5927万+16.22%
10/13303306292296-3.9%353,80087億1210万+15.63%
10/12309313291308-1.91%789,40090億6530万+21.74%
10/11319332312314-3.98%580,70092億4189万+26.1%
10/07333350311327-8.4%2,888,50096億2452万+33.47%
10/06273357273357+28.88%2,362,800105億750万+48.13%
10/05281284267277+0.73%553,50081億5288万+17.87%
10/0415:00 神経疼痛治療薬「DW-5LBT」今後の見通しについて
10/04261278255275+4.56%495,70080億9402万+18.53%
10/03241264235263+9.58%528,70077億4082万+14.35%
09/30238245235240-1.23%124,50070億6387万+5.26%
09/29226246226243+9.46%461,20071億5217万+7.05%
09/28237237220222-6.72%183,70065億3408万-1.33%
09/27243245228238-0.42%390,10070億500万+5.78%
09/2615:30 緑内障・高眼圧症治療剤「K-232(販売名:グラアルファ配合点眼液)」の国内製造販売承認取得のお知らせ
09/26234239233239+0.84%103,00070億3443万+6.7%
09/22232238231237+0.85%80,00069億7557万+6.28%
09/21237237231235-1.26%65,70069億1670万+5.86%
09/20236238233238+2.15%120,90070億500万+7.69%
09/16238238231233-0.85%61,50068億5784万+5.91%
09/15240241235235+1.29%118,40069億1670万+7.31%
09/14225233225232+1.31%53,10068億2840万+6.42%
09/13236238229229-1.72%73,10067億4011万+5.05%
09/12237241233233-2.1%90,90068億5784万+7.37%
09/09241242230238-0.83%233,30070億500万+9.68%
09/08228247226240+5.73%579,90070億6387万+11.11%
09/07225227220227+1.79%130,90066億8124万+5.58%
09/06217224217223+2.76%136,90065億6351万+3.72%
09/05217218213217+0.46%78,80063億8691万+0.93%
09/02223251216216+0.47%1,126,50063億5748万+0.47%
09/01212215211215+0.94%35,70063億2805万-0.46%
08/31211213211213+0.47%21,00062億6918万-1.39%
08/30212212211212+0.95%13,70062億3975万-1.85%
08/29212213209210-1.41%43,70061億8088万-2.78%
08/2615:30 フックス角膜内皮変性症治療剤「K-321」の米国における第III相臨床試験開始のお知らせ
08/26213214211213-0.47%25,50062億6918万-1.84%
08/252132152112140%17,50062億9861万-1.38%
08/24212218211214+0.47%51,90062億9861万-1.38%
08/23213213211213+0.47%44,50062億6918万-1.84%
08/22213215212212-1.85%30,20062億3975万-2.3%
08/19212217211216+1.41%36,50063億5748万0%
08/18210215209213+1.43%38,90062億6918万-1.39%
08/172102122092100%22,70061億8088万-2.78%
08/16209214209210+0.96%27,60061億8088万-2.78%
08/15214214208208-1.89%60,80061億2202万-3.26%
08/12213218212212-1.4%30,90062億3975万-1.4%
08/10214216208215-1.38%83,70063億2805万0%
08/0915:30 営業外収益及び営業外費用の計上に関するお知らせ
08/0915:30 2022年12月期第2四半期決算説明資料
08/0915:30 2022年12月期第2四半期決算短信〔日本基準〕(連結)
08/09218223217218+1.4%37,00064億1635万+1.4%
08/08222222213215-3.59%65,70063億2805万+0.47%
08/052252262212230%56,60065億6351万+4.21%
08/04220224220223+1.36%21,90065億6351万+4.69%
08/03221221216220-1.35%20,60064億7521万+3.77%
08/02217224216223+1.83%38,10065億6351万+5.19%